姚享章,岑 朝,覃桥莉

肠道菌群是人体内重要的微生物群，在人体内发挥着调节身体免疫系统、协助机体消化食物和吸收养分和促进代谢废物排出等关键作用。近年来研究发现非酒精性脂肪肝、肝硬化等慢性肝病的发生发展与肠道菌群有着密切关联，并逐渐成为近年来的研究热点，本文就肠道菌群与慢性肝病的关系及靶向肠道菌群治疗肝脏疾病进行系统评述。

肠道菌群；靶向肠道菌群治疗；肝病；肝硬化

[1] Adak A,Khan MR.An insight into gut microbiota and its functionalities.Cell Mol Life Sci.2019 Feb;76(3):473-493. [2] 乔一腾.产细菌素乳酸片球菌对小鼠肠道生理功能的作用研究[D].江南大学,2021. [3] Tap J,Mondot S,Levenez F,Pelletier E,Caron C,Furet JP,Ugarte E,Muñoz-Tamayo R,Paslier DL,Nalin R,Dore J,Leclerc M.Towards the human intestinal microbiota phylogenetic core.Environ Microbiol.2009 Oct;11(10):2574-84. [4] Trebicka J,Bork P,Krag A,Arumugam M.Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.Nat Rev Gastroenterol Hepatol.2021 Mar;18(3):167-180. [5] Guilloteau P,Martin L,Eeckhaut V,Ducatelle R,Zabielski R,Van Immerseel F.From the gut to the peripheral tissues:the multiple effects of butyrate.Nutr Res Rev.2010 Dec;23(2):366-84. [6] Hsu CL,Schnabl B.The gut-liver axis and gut microbiota in health and liver disease.Nat Rev Microbiol.2023 Nov;21(11):719-733. [7] de Vos WM,Tilg H,Van Hul M,Cani PD.Gut microbiome and health:mechanistic insights.Gut.2022 May;71(5):1020-1032. [8] Fang J,Yu CH,Li XJ,Yao JM,Fang ZY,Yoon SH,Yu WY.Gut dysbiosis in nonalcoholic fatty liver disease:pathogenesis,diagnosis,and therapeutic implications.Front Cell Infect Microbiol.2022 Nov 8;12:997018. [9] Miele L,Valenza V,La Torre G,Montalto M,Cammarota G,Ricci R,MascianàR,Forgione A,Gabrieli ML,Perotti G,Vecchio FM,Rapaccini G,Gasbarrini G,Day CP,Grieco A.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology.2009 Jun;49(6):1877-87. [10] Tilg H,Adolph TE,Trauner M.Gut-liver axis:Pathophysiological concepts and clinical implications.Cell Metab.2022 Nov 1; 34(11):1700-1718. [11] Wu MY,Fan JG.Gut microbiome and nonalcoholic fatty liver disease.Hepatobiliary Pancreat Dis Int.2023 Oct;22(5):444-451. [12] Wahlström A,Sayin SI,Marschall HU,Bäckhed F.Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.Cell Metab.2016 Jul 12;24(1):41-5. [13] Lee G,You HJ,Bajaj JS,Joo SK,Yu J,Park S,Kang H,Park JH,Kim JH,Lee DH,Lee S,Kim W,Ko G.Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.Nat Commun.2020 Oct 5;11(1):4982. [14] 张婷,李军,刘淬平,等.肠道菌群在酒精性脂肪肝中的作用及相关机制研究[J].海南医学院学报,2018,24(24):2112-2116 [15] 柳惠未,叶桦.肠道菌群在非酒精性脂肪性肝病发病机制中的作用[J].中国现代医生,2019,57(06):163-168. [16] Grander C,Adolph TE,Wieser V,Lowe P,Wrzosek L,Gyongyosi B,Ward DV,Grabherr F,Gerner RR,Pfister A,Enrich B,Ciocan D, Macheiner S,Mayr L,Drach M,Moser P,Moschen AR,Perlemuter G,Szabo G,Cassard AM,Tilg H.Recovery of ethanolinduced Akkermansia muciniphila depletion ameliorates alcoholic liver disease.Gut.2018 May;67(5):891-901. [17] Zhao XH,Cao ZY,Shen Y,Lv YF,Tao GR,Chen S.Influence of Chongcao Yigan Capsule on function of intestinal flora and chemoprevention for patients with chronic hepatitis B-induced liver fibrosis.Asian Pac J Cancer Prev.2014;15(21):9423-6. [18] Chou HH,Chien WH,Wu LL,Cheng CH,Chung CH,Horng JH,Ni YH,Tseng HT,Wu D,Lu X,Wang HY,Chen PJ,Chen DS.Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota.Proc Natl Acad Sci U S A.2015 Feb 17; 112(7):2175-80. [19] Chen Y,Chen Z,Guo R,Chen N,Lu H,Huang S,Wang J,Li L.Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection.Diagn Microbiol Infect Dis.2011 Aug;70(4):492-8. [20] Hiramatsu K,Harada K,Tsuneyama K,Sasaki M,Fujita S,Hashimoto T,Kaneko S,Kobayashi K,Nakanuma Y.Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis.J Hepatol. 2000 Jul;33(1):9-18. [21] Yu LX,Schwabe RF.The gut microbiome and liver cancer:mechanisms and clinical translation.Nat Rev Gastroenterol Hepatol.2017 Sep;14(9):527-539. [22] Zhou WC,Zhang QB,Qiao L.Pathogenesis of liver cirrhosis.World J Gastroenterol.2014 Jun 21;20(23):7312-24. [23] Qin N,Yang F,Li A,Prifti E,Chen Y,Shao L,Guo J,Le Chatelier E,Yao J,Wu L,Zhou J,Ni S,Liu L,Pons N,Batto JM,Kennedy SP,Leonard P,Yuan C,Ding W,Chen Y,Hu X,Zheng B,Qian G,Xu W,Ehrlich SD,Zheng S,Li L.Alterations of the human gut microbiome in liver cirrhosis.Nature.2014 Sep 4;513(7516):59-64. [24] Lin R,Zhou L,Zhang J,Wang B.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis.Int J Clin Exp Pathol.2015 May 1;8(5):5153-60. [25] Qian Q,He W,Tang R,Ma X.Implications of gut microbiota in autoimmune liver diseases.Minerva Gastroenterol(Torino).2023 Mar; 69(1):95-106. [26] Lv LX,Fang DQ,Shi D,Chen DY,Yan R,Zhu YX,Chen YF,Shao L,Guo FF,Wu WR,Li A,Shi HY,Jiang XW,Jiang HY,Xiao YH,Zheng SS,Li LJ.Alterations and correlations of the gut microbiome,metabolism and immunity in patients with primary biliary cirrhosis.Environ Microbiol.2016 Jul;18(7):2272-86. [27] Bajaj JS,Heuman DM,Sanyal AJ,Hylemon PB,Sterling RK,Stravitz RT,Fuchs M,Ridlon JM,Daita K,Monteith P,Noble NA,White MB, Fisher A,Sikaroodi M,Rangwala H,Gillevet PM.Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.PLoS One.2013;8(4):e60042. [28] Quraishi MN,Sergeant M,Kay G,Iqbal T,Chan J,Constantinidou C,Trivedi P,Ferguson J,Adams DH,Pallen M,Hirschfield GM.The gut- adherent microbiota of PSC-IBD is distinct to that of IBD.Gut.2017 Feb;66(2):386-388. [29] Rühlemann M,Liwinski T,Heinsen FA,Bang C,Zenouzi R,Kummen M,Thingholm L,Tempel M,Lieb W,Karlsen T,Lohse A,Hov J,Denk G,Lammert F,Krawczyk M,Schramm C,Franke A.Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis.Aliment Pharmacol Ther.2019 Sep;50(5):580-589. [30] Nakamoto N,Sasaki N,Aoki R,Miyamoto K,Suda W,Teratani T,Suzuki T,Koda Y,Chu PS,Taniki N,Yamaguchi A,Kanamori M,Kamada N,Hattori M,Ashida H,Sakamoto M,Atarashi K,Narushima S,Yoshimura A,Honda K,Sato T,Kanai T.Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis.Nat Microbiol.2019 Mar;4(3):492-503. [31] Gómez-Hurtado I,Such J,Francés R.Microbiome and bacterial translocation in cirrhosis.Gastroenterol Hepatol.2016 Dec;39(10): 687-696.English,Spanish. [32] Shao L,Ling Z,Chen D,Liu Y,Yang F,Li L.Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression:A Meta- Omics-Based Study.Front Microbiol.2018 Dec 18;9:3166 [33] 张绍全,林炳亮.肠道菌群与肝硬化研究进展[J].实用肝脏病杂志,2023,26(03):313-316. [34] 徐小元,丁惠国,李文刚,等.肝硬化肝性脑病诊疗指南(2018年,北京)[J].中华胃肠内镜电子杂志,2018,5(03):97-113. [35] Bajaj JS,Ridlon JM,Hylemon PB,Thacker LR,Heuman DM,Smith S,Sikaroodi M,Gillevet PM.Linkage of gut microbiome with cognition in hepatic encephalopathy.Am J Physiol Gastrointest Liver Physiol.2012 Jan 1;302(1):G168-75. [36] NOUE T,NAKAYAMA J,MORIYA K,et al.Gut dysbiosis as‐sociated with hepatitis C virus infection[J].Clinical Infectious Diseases,2018,67(6):869-877. [37] aZ,Lv H,Lv J,Shi Y,Huang H,Chen L,Shi D.Alterations of gut microbiota in cirrhotic patient,2018,56(6):869-569. [38] Bajaj JS,Heuman DM,Hylemon PB,Sanyal AJ,White MB,Monteith P,Noble NA,Unser AB,Daita K,Fisher AR,Sikaroodi M,Gillevet PM.Altered profile of human gut microbiome is associated with cirrhosis and its complications.J Hepatol.2014 May;60(5):940-7. [39] Deng YD,Peng XB,Zhao RR,Ma CQ,Li JN,Yao LQ.The intestinal microbial community dissimilarity in hepatitis B virus-related liver cirrhosis patients with and without at alcohol consumption.Gut Pathog.2019 Nov 26;11:58. [40] Liu R,Kang JD,Sartor RB,Sikaroodi M,Fagan A,Gavis EA,Zhou H,Hylemon PB,Herzog JW,Li X,Lippman RH,Gonzalez-Maeso J, Wade JB,Ghosh S,Gurley E,Gillevet PM,Bajaj JS.Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant.Hepatology.2020 Feb;71(2):611-626. [41] Bajaj JS,Salzman NH,Acharya C,Sterling RK,White MB,Gavis EA,Fagan A,Hayward M,Holtz ML,Matherly S,Lee H,Osman M,Siddiqui MS,Fuchs M,Puri P,Sikaroodi M,Gillevet PM.Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy:A Phase 1,Randomized,Placebo-Controlled Trial.Hepatology.2019 Nov;70(5):1690-1703. [42] Tietz T,Lenzner A,Kolbaum AE,Zellmer S,Riebeling C,Gürtler R,Jung C,Kappenstein O,Tentschert J,Giulbudagian M,Merkel S,Pirow R,Lindtner O,Tralau T,Schäfer B,Laux P,Greiner M,Lampen A,Luch A,Wittkowski R,Hensel A.Aggregated aluminium exposure:risk assessment for the general population.Arch Toxicol.2019 Dec;93(12):3503-352. [43] Zacharias HD,Kamel F,Tan J,Kimer N,Gluud LL,Morgan MY.Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.Cochrane Database Syst Rev.2023 Jul 19;7(7):CD011585.

点击下载PDF